Law Firm Launches Shareholder Investigation Into Priority Technology Over 50% Stock Decline

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Law firm Kaskela initiates shareholder investigation into Priority Technology over 50% stock decline since February, examining potential securities violations and fiduciary duty breaches.

Law Firm Launches Shareholder Investigation Into Priority Technology Over 50% Stock Decline

Kaskela Law LLC has initiated a formal investigation into Priority Technology Holdings Inc. (NASDAQ: PRTH) to examine potential securities law violations and breaches of fiduciary duty by company officers and directors. The investigation comes as Priority Technology's stock has experienced a significant decline, dropping more than 50% since February 2025, falling from over $12.00 per share to below $6.00 per share.

The law firm is accepting inquiries from Priority Technology shareholders who may have experienced losses during this period. Similar investigations have been launched into two other publicly traded companies: BARK Inc. (NYSE: BARK) and Marblegate Capital Corp. (OTC: MGTE). These parallel investigations suggest a broader pattern of shareholder concerns regarding corporate governance and management conduct.

Investigations of this nature typically examine whether company leadership failed to disclose material information, mismanaged assets, or otherwise violated their obligations to shareholders. Priority Technology shareholders who wish to participate in the investigation or have information relevant to the firm's inquiry are being encouraged to contact Kaskela Law LLC directly.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 13

Related Coverage

GlobeNewswire Inc.

Sika AG Shareholders Approve Board, Boost Dividend to CHF 3.70 Per Share

Sika AG shareholders approved CHF 3.70 dividend and board re-election at 2026 AGM, with company reporting CHF 11.20B sales and 33,700 employees globally.

SXYAY
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

MVST Stock Plunges 34% After Disastrous Earnings; Law Firm Launches Fraud Investigation

Microvast ($MVST) plunged 34% after reporting $96.5M revenue (29% below consensus) and 1% gross margins, triggering securities fraud investigation by Pomerantz LLP.

MVSTMVSTW
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX